Silencing mutant TP53 through siRNA has been demonstrated to impede the growth of specific tumor cells in vitro and in vivo, enhancing their susceptibility to cytotoxic drugs (Wang et al. 2022). This evidence concerns the gene TP53 and neoplasm.